Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound

PURPOSE: Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of (21...

Descripción completa

Detalles Bibliográficos
Autores principales: Watabe, Tadashi, Kaneda-Nakashima, Kazuko, Shirakami, Yoshifumi, Kadonaga, Yuichiro, Ooe, Kazuhiro, Wang, Yang, Haba, Hiromitsu, Toyoshima, Atsushi, Cardinale, Jens, Giesel, Frederik L., Tomiyama, Noriyuki, Fukase, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852121/
https://www.ncbi.nlm.nih.gov/pubmed/36344651
http://dx.doi.org/10.1007/s00259-022-06016-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852121/
https://www.ncbi.nlm.nih.gov/pubmed/36344651
http://dx.doi.org/10.1007/s00259-022-06016-z

Ejemplares similares